Sanofi India Faces ₹12.37 Crore Tax Demand, Plans Appeal

Sanofi India Limited announced it has received a final tax assessment order for fiscal year 2022-23 from the Income Tax Department.

The order determines a tax liability of ₹12.37 crore, including applicable interest.

The assessment stems from adjustments concerning transfer pricing and disallowed payments to healthcare professionals.

The company has stated its intention to appeal this order before higher tax authorities.

Why This Matters

While not immediately material, the tax demand signals a potential financial outflow and ongoing legal challenges.

These adjustments can indicate scrutiny of the company's inter-company transactions and expenses, requiring careful management.

The company's decision to appeal suggests it believes there are valid grounds to contest the tax department's findings.

The Backstory

Sanofi India has navigated complex tax matters previously. In 2013, an Indian High Court quashed a ₹1000 crore capital gains tax demand related to its 2009 acquisition of Shantha Biotechnics, ruling that tax was chargeable in France under a double taxation treaty.

More recently, in January 2025, the company received another transfer pricing order for Assessment Year 2022-23, levying a tax of ₹26.50 crore due to disallowed international transactions. Sanofi India had then stated its intent to appeal this order and noted it had no material impact on its operations.

What Changes Now

Sanofi India must account for the ₹12.37 crore tax liability, which could impact its financial statements if not fully provisioned.

A formal appeal process is now underway.

The appeal's outcome will determine if the tax demand is reversed or confirmed.

This event highlights the ongoing regulatory focus on transfer pricing within the pharmaceutical sector.

Risks to Watch

• Legal & Financial: If the appeal is unsuccessful, Sanofi India could be liable for the full tax demand, along with potential penalties and further interest.
• Reputational: Persistent tax disputes can sometimes affect investor sentiment.
• Operational: Prolonged litigation could divert management focus.

Peer Comparison

Sanofi India operates in a competitive landscape alongside major pharmaceutical players like Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., and Zydus Lifesciences Ltd. The pharmaceutical sector often faces scrutiny from tax authorities regarding transfer pricing of goods and services, as well as expenses related to marketing and healthcare professional engagement.

Context Metrics

For the fiscal year ended December 2023, Sanofi India reported Net Sales of ₹28,511 million (approximately ₹2,851.1 crore) and Profit After Tax of ₹6,029 million (approximately ₹602.9 crore) on a consolidated basis.

What to Track Next

• The progress and outcome of Sanofi India's appeal against the ₹12.37 crore tax assessment order.
• Any further disclosures from the company regarding the appeal proceedings.
• The final resolution of tax disputes impacting the company's financial health.